US Food and Drug Administration Commissioner Robert Califf believes larger clinical trials may be necessary to ensure research adequately reflects the diverse needs of patients.
Key Takeaways
-
Robert Califf called for much larger clinical trials to ensure treatment effects can be studied in subgroups of interest.
-
He said the field should recognize its advancements in diversity so far, but trials also should include subgroups, such as the elderly and rural residents
During a recent National Academies of Science, Engineering and Medicine workshop on clinical trial diversity, Califf took a deliberately provocative tone, reflective of someone nearing the end of a long career in drug development, which was capped by two tenures as head of the FDA
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?